Skip to main content Skip to main navigation menu Skip to site footer
logo Dermatology Reports

eISSN 2036-7406

  • About the Journal
  • Publication Ethics
  • Editorial Board
  • Current Issue
  • Archives
  • Early Access
  • Guidelines for Authors
  • Register
  • Login
  • Search
  • Contacts

Editor-in-Chief: Carlo Cota, Italy

1.0
Impact Factor 2025
1.5
CiteScore 2025
1.0
Impact Factor 2025
1.5
CiteScore 2025
Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • New and emerging therapies in cutaneous T-cell lymphoma

    Gabriele Roccuzzo, Nicole Macagno, Silvia Giordano, Paolo Fava, Pietro Quaglino
    02-10-2024
    https://doi.org/10.4081/dr.2024.10002
    1230
    PDF: 696
    HTML: 110
  • Clinical features, safety, and efficacy of combining Q-switched Nd:YAG laser and FOB® Tri-White Serum in melasma treatment

    Thi Xuan Tam Huynh, Bay Quach Thi
    02-09-2025
    https://doi.org/10.4081/dr.2025.10270
    820
    PDF: 324
    HTML: 21
  • Vitiligo: What’s old, what’s new

    Mariabeatrice Bertolani, Eleonora Rodighiero, Maria Beatrice de Felici del Giudice, Torello Lotti, Claudio Feliciani, Francesca Satolli
    15-09-2021
    https://doi.org/10.4081/dr.2021.9142
    2922
    PDF: 1198
    HTML: 233
  • Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome

    Shinta Trilaksmi Dewi, Laily Noor Qomariah, Widya Khairunisa Sarkowi, Monika Puspitasari, Miya Khalidah, Marcella Anggatama, Dwinanda Almira Rizkiani, Kristiana Etnawati, Sri Awalia Febriana
    19-06-2023
    https://doi.org/10.4081/dr.2023.9656
    1359
    PDF: 669
    HTML: 199
  • Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols

    François Pélouard, Valérie Chedru-Legros, Catherine Nganoa, Anne Dompmartin, Jean-Matthieu L'Orphelin
    15-04-2025
    https://doi.org/10.4081/dr.2025.10036
    903
    PDF: 370
    SUPPLEMENTARY MATERIAL: 106
    HTML: 14
  • Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

    Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi
    01-10-2018
    https://doi.org/10.4081/dr.2018.7859
    2140
    PDF: 1100
    HTML: 91
  • Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study

    Mario Valenti, Sara Di Giulio, Andrea Carugno, Pasquale Frascione, Angelo Valerio Marzano, Santo Raffaele Mercuri, Gianluca Nazzaro, Giulia Spallone, Giovanni Paolino, Marco Ardigò
    18-02-2025
    https://doi.org/10.4081/dr.2025.10196
    683
    PDF: 577
    HTML: 28
  • Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: A single-center study and a new dedicated therapeutic protocol

    Vincenzo De Giorgi, Luciana Trane, Giulia Pieretti, Nicola Santoro, Flavia Silvestri , Federico Venturi, Federica Scarfi, Vincenza Maio, Giuseppe Spinelli, Silvia Scoccianti, Laura Guerrini, Daniela Massi, Cinzia Mazzini, Laura Doni
    05-08-2021
    https://doi.org/10.4081/dr.2021.9240
    3389
    PDF: 725
    HTML: 20
  • Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

    Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti
    12-11-2024
    https://doi.org/10.4081/dr.2024.10080
    1387
    PDF: 757
    HTML: 50
  • Rilzabrutinib-induced transition from pemphigus vulgaris to pemphigus foliaceous: a case report and literature review

    Christian Ciolfi, Jacopo Tartaglia, Francesca Pampaloni, Laura Fagotto, Andrea Sechi, Mauro Alaibac
    23-10-2024
    https://doi.org/10.4081/dr.2024.10010
    709
    PDF: 406
    SUPPLEMENTARY MATERIAL: 184
    HTML: 50
  • Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights

    Roberto D'Astolto, Lavinia Quintarelli, Alberto Corrà, Marzia Caproni, Luca Fania, Giovanni Di Zenzo, Biagio Didona, Giulia Gasparini, Emanuele Cozzani, Claudio Feliciani
    14-06-2023
    https://doi.org/10.4081/dr.2023.9641
    1107
    PDF: 517
    HTML: 34
  • Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies

    Edoardo Mortato, Silvia Baratta, Luca Rubino, Anna Paola De Caro, Francesco Loconsole
    19-06-2023
    https://doi.org/10.4081/dr.2023.9755
    911
    PDF: 443
    HTML: 26
  • The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review

    Elena Pezzolo, Sara Di Leo, Paola Miceli, Alvise Sernicola, Luigi Naldi
    01-07-2025
    https://doi.org/10.4081/dr.2025.10112
    1040
    PDF: 771
    HTML: 42
  • Efficacy of autologous serum therapy in positive and negative autologous serum skin test patients in chronic urticaria in a tertiary care centre

    Raghavendra KR, Bangaru H
    06-07-2022
    https://doi.org/10.4081/dr.2022.9525
    2189
    PDF: 595
    HTML: 75
  • Therapeutic management of a symptomatic Kaposi’s sarcoma patient with renal failure undergoing haemodialysis: A case report

    Anna Passarelli, Giovanna Galdo, Teresa Pellegrino, Giandomenico Roviello, Michele Aieta, Gabriella Aviello, Raffaele Conca
    29-10-2021
    https://doi.org/10.4081/dr.2022.9113
    2572
    PDF: 671
    HTML: 27
  • New therapeutic applications of ozenoxacin in superficial skin infections

    Gema García Ron, María Villa Arranz
    05-08-2021
    https://doi.org/10.4081/dr.2021.9289
    2877
    PDF: 928
    Supplementary Files: 458
    HTML: 25
  • Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2– breast cancer

    Edoardo Mortato, Anna Paola De Caro, Luca Schinzari, Sonia Maniglio, Carmelo Laface, Gerardo Cazzato, Caterina Foti, Francesca Ambrogio
    19-11-2024
    https://doi.org/10.4081/dr.2024.10144
    729
    PDF: 432
    HTML: 47
  • Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

    Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota
    11-11-2024
    https://doi.org/10.4081/dr.2024.10140
    1097
    PDF: 581
    SUPPLEMENTARY MATERIAL: 189
    HTML: 24
  • Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies

    Claudia Paganini, Edoardo Mortato, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo
    04-03-2025
    https://doi.org/10.4081/dr.2025.10193
    1397
    PDF: 621
    HTML: 47
  • Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib

    Haruhiko Otsuka, Takeshi Fukumoto, Naomi Kiyota, Chihiro Takemori, Haruki Jimbo, Chikako Nishigori
    01-01-2022
    https://doi.org/10.4081/dr.2022.9303
    1714
    PDF: 645
    HTML: 22
  • Attitudes among dermatologists regarding actinic keratosis treatment options

    Gaia Moretta, Tonia Samela, Francesca Sampogna, Francesco Ricci, Fabio Carlesimo, Annarita Panebianco, Angelo Massimiliano D’Erme, Giovanni Di Lella, Sabatino Pallotta, Elena Dellambra, Damiano Abeni, Luca Fania
    31-01-2022
    https://doi.org/10.4081/dr.2022.9392
    1147
    PDF: 695
    HTML: 40
  • Late reaction to ustekinumab infusion

    Marina Resener Morais, Luana Pizarro Meneghello, Carina Flores de Oliveira, André Vicente Esteves Carvalho
    e2
    09-09-2013
    https://doi.org/10.4081/dr.2013.e2
    4011
    PDF: 696
    HTML: 270
  • Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

    Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly
    21-11-2022
    https://doi.org/10.4081/dr.2022.9265
    1582
    PDF: 474
    HTML: 37
  • Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

    Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza
    21-11-2022
    https://doi.org/10.4081/dr.2022.9447
    1433
    PDF: 432
    HTML: 54
  • Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease

    Klaudia Miklusiak, Karol Miklusiak, Olga Kaczmarczyk, Dorota Cibor, Małgorzata Zwolińska-Wcisło
    22-05-2023
    https://doi.org/10.4081/dr.2023.9630
    1123
    PDF: 593
    HTML: 98
26 - 50 of 103 items << < 1 2 3 4 5 > >> 

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a Scientific paper
  • How to write a Review article
  • Article Processing Charge
  • Crediti ECM (Italian Authors)

reviewers

FOR REVIEWERS
  • Benefits for Reviewers
  • How to Review
  • Thanks to Reviewers

Categories

    • Newsletter
    • Original Articles
    • Reviews
    • Case Reports

indexing

INDEXING
  • PubMed
  • PubMed Central
  • Scopus
  • DOAJ
  • ESCI
  • Google Scholar
  • OpenAlex
  • Web of Science
  • Analytics

dermatopathology

Dermatopathology

Dermatology Reports

is an Open Access, peer-reviewed journal published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.

 

https://godisnjak.pf.unibl.org/

https://revistascientificas.us.es/

pISSN: 2036-7392
eISSN: 2036-7406

Info

  • About
  • Editorial Board
  • News
  • Advertising

Info Submission

  • Submission
  • Guidelines For Authors

Our App Is Free For Anyone!

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.